9th Neuropsychiatric Drug Development Summit

Memo

Despite high-profile Phase II/III setbacks, neuropsychiatric drug development is entering a renewed phase of momentum. From the Delix’s non-hallucinogenic neuroplastogens and MapLight’s muscarinic push following a $250M IPO, to COMPASS Pathways advancing toward the first psychedelic approval, to the FDA plan to expedite psychedelic development, industry commitment to tackling the most persistent mental health challenges has never been stronger. With hundreds of programs spanning depression, schizophrenia, psychosis, anxiety, sleep and SUDs, and surging investment across psychedelics, muscarinics, orexins, serotonergic agonists and novel modalities, confidence is returning. Learnings from 2025 failures are driving more resilient strategies, grounded in biology-first hypotheses, smarter patient stratification, EEG and digital biomarkers, sleep and speech endpoints, and regulatory-ready translational frameworks, to finally overcome placebo effects, heterogeneity, and late-stage attrition. Uniting 150+ senior leaders across discovery, preclinical, translational, clinical, regulatory and investment, with 44+ speakers from AbbVie, Gilgamesh, Otsuka, Neumora, Lundbeck, Boehringer Ingelheim, Bristol Myers Squibb, Monument Therapeutics, COMPASS Pathways, Karuna Therapeutics, Alto Neuroscience, Eli Lilly and more, the 9th Neuropsychiatric Drug Development Summit is the definitive forum accelerating the next era of precision psychiatry and patient-centered mental health innovation. URLs:Tickets: https://go.evvnt.com/3627083-2?pid=5569Brochure: https://go.evvnt.com/3627083-3?pid=5569 Date and Time: On Tue, 15 Sep 2026 08:00 - Thu, 17 Sep 2026 17:00 Venue Details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine Prices:Conference Only - Primary: USD 2699.00,Full Package - Conference + Workshop/Focus Day - Primary: USD 3597.00,Conference Only - Discounted: USD 2299.00,Full Package - Conference + Workshop/Focus Day - Discounted: USD 2997.00,Conference Only - Vendor: USD 3899.00Full Package - Conference + Workshop/Focus Day: USD 5397.00 Speakers: Derek Buhl, Scientific Director, AbbVie, Chris Ocampo, Head of Psychiatry, Neuroscience Clinical Development, Abbvie, Lawrence Park, Senior Medical Director, Clinical Development, AbbVie, Samir Koirala, Vice President and Head of Neurobiology Research, Alkermes, James Cronican, Head Vice President, Experimental Medicine Neuroscience and Mental Health, Boehringer Ingelheim, Pranab Kalita, Head of Clinical Development, Experimental Medicine, Neuroscience and Mental Health, Boehringer Ingelheim, Gerard Zitnik, Director, Worldwide Medical Neuroscience, Bristol Myers Squibb, Johan Luthman, Head Executive VP, Research and Development, Lundbeck, Veronika Logonvinsky, VP Clinical Devlopment, Lundbeck, Matt Harlin, Senior Director, Discovery Research, Otsuka Pharmaceutical Companies (U.S.), Steve Levine, Chief Patient Officer, COMPASS Pathways, Guy Goodwin, Chief Medical Officer, COMPASS Pathways, Zoe Hughes, Vice President Biology and Translational Medicine, Gilgamesh Pharmaceuticals, Amir Inamdar, Chief Medical Officer, Helus Pharma, Andrew Miller, Founder, Karuna Therapeutics, Jens Wendland, Chief Medical Officer, Kynexis Therapeutics, Jenny Barnett, Co-Founder and Chief Executive Officer, Monument Therapeutics, Nick Brandon, Chief Scientific Officer, Neumora, Mikhail Kalinichev, Chief Executive Officer, Neurosterix, Magali Haas, Chief Medical Officer, Psilera, Michael Chen, Chief Scientific Officer, Seaport Therapeutics, Aaron Koenig, Chief Medical Officert, Syndeio Biosciences, Sam Banister, Co-founder and Chief Scientific Officer, XYLO Therapeutics, Eloise Jarvis, Researcher, Beacon Research Operations, Ritu Baralt, Managing Director, Health Care - Biotechnology Research Analyst, Cowen, Peter Stein, NextStage Pharma Consulting, Former Director, Office of New Drugs, CDER, FDA, Jason Pitts, Principal, General Atlantic, Natalie Sacks, Partner, Novo Holdings US, Paul Matteis, Managing Director and Head of Therapeutics Research, Stifel, Chris Weyrer, Venture Capital Life Science Professional, Vida Ventures, Zohreh Farsi, Group Leader, Research Scientist I, Broad Institute, Stephanie R Jones, Professor of Neuroscience, Brown University, Ernest Pedapati, Professor, UC Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital, Craig Erickson, Associate Professor, Cincinnati Children’s Hospital, Rouba Kozak, Former Director of Mental Health, Translational Sciences, FNIH, Joseph T. Coyle, Director, Laboratory for Psychiatric and Molecular Neuroscience, McLean Hospital, Eben S. Draper Professor of Psychiatry, Harvard Medical School, Jordan Smoller, Professor of Psychiatry, Harvard Medical School, Scott Thompson, Professor, Department of Psychiatry, University of Colorado School of Medicine, John Salamone, Board of Trustees Distinguished Professor and Director of Behavioral Neuroscience Professor, University of Connecticut, Marco Pignatelli, Assistant Professor of Psychiatry, WashU Medicine, Shobi Ahmed, Founder and Chief Executive Officer, Sama Therapeutics, John Huxter, Associate Director and Head of Rodent EEG, Transpharmation, Enya Paschen, Head of preclinical neuropharmacology, Ulysses Neuroscience